GH Research Presents GH001-TRD-201 Trial Data at ECNP Meeting
Ticker: GHRS · Form: 6-K · Filed: Oct 14, 2025 · CIK: 1855129
Sentiment: neutral
Topics: clinical-trial-data, conference-presentation, pharmaceuticals
TL;DR
GH Research dropped data from its GH001-TRD-201 trial at the ECNP meeting on Oct 13th.
AI Summary
GH Research PLC announced on October 14, 2025, that data from its GH001-TRD-201 clinical trial was presented at the 38th European College of Neuropsychopharmacology (ECNP) annual meeting in Amsterdam. The presentation, delivered by Prof. Wiesław J. Cubała on October 13, 2025, focused on Novel Therapies.
Why It Matters
The presentation of clinical trial data at a major scientific conference like ECNP is a key step in the drug development process, potentially impacting future regulatory approvals and market perception.
Risk Assessment
Risk Level: medium — Clinical trial data presentations are important but do not guarantee regulatory approval or commercial success, carrying inherent risks associated with drug development.
Key Numbers
- 38th — ECNP Meeting Edition (Indicates the significance and established nature of the conference.)
Key Players & Entities
- GH Research PLC (company) — Registrant
- GH001-TRD-201 (clinical_trial) — Trial name
- 38th European College of Neuropsychopharmacology (ECNP) annual meeting (event) — Conference where data was presented
- October 11-14, 2025 (date) — Date of ECNP meeting
- Amsterdam, the Netherlands (location) — Location of ECNP meeting
- Prof. Wiesław J. Cubała (person) — Presenter of trial data
- October 13, 2025 (date) — Date of presentation
FAQ
What specific data from the GH001-TRD-201 trial was presented?
The filing states that data from the GH001-TRD-201 clinical trial was presented, but does not specify the exact nature or results of the data.
Who presented the data at the ECNP meeting?
Prof. Wiesław J. Cubała, MD, PhD, presented the data on October 13, 2025.
When and where did the ECNP annual meeting take place?
The 38th ECNP annual meeting took place from October 11-14, 2025, in Amsterdam, the Netherlands.
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer for the month of October 2025, announcing the presentation of clinical trial data.
Does the filing provide any financial information or guidance?
No, this specific filing (Form 6-K) focuses on the announcement of clinical trial data presentation and does not contain financial information or guidance.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2025-10-14 07:00:19
Filing Documents
- ef20056726_6k.htm (6-K) — 9KB
- ef20056726_ex99-1.htm (EX-99.1) — 41KB
- ef20056726_ex99-1slide01.jpg (GRAPHIC) — 84KB
- ef20056726_ex99-1slide02.jpg (GRAPHIC) — 168KB
- ef20056726_ex99-1slide03.jpg (GRAPHIC) — 184KB
- ef20056726_ex99-1slide04.jpg (GRAPHIC) — 127KB
- ef20056726_ex99-1slide05.jpg (GRAPHIC) — 130KB
- ef20056726_ex99-1slide06.jpg (GRAPHIC) — 104KB
- ef20056726_ex99-1slide07.jpg (GRAPHIC) — 98KB
- ef20056726_ex99-1slide08.jpg (GRAPHIC) — 84KB
- ef20056726_ex99-1slide09.jpg (GRAPHIC) — 72KB
- ef20056726_ex99-1slide10.jpg (GRAPHIC) — 79KB
- ef20056726_ex99-1slide11.jpg (GRAPHIC) — 75KB
- ef20056726_ex99-1slide12.jpg (GRAPHIC) — 67KB
- ef20056726_ex99-1slide13.jpg (GRAPHIC) — 98KB
- ef20056726_ex99-1slide14.jpg (GRAPHIC) — 142KB
- ef20056726_ex99-1slide15.jpg (GRAPHIC) — 81KB
- ef20056726_ex99-1slide16.jpg (GRAPHIC) — 93KB
- ef20056726_ex99-1slide17.jpg (GRAPHIC) — 139KB
- ef20056726_ex99-1slide18.jpg (GRAPHIC) — 72KB
- 0001140361-25-038026.txt ( ) — 2663KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F GH Research PLC announces the presentation of data from its GH001-TRD-201 clinical trial at the 38 th European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands (the "Congress"). A copy of the presentation delivered by Prof. Wiesaw J. Cubaa, MD, PhD, on October 13, 2025, as part of the Novel Therapies Symposium during the Congress, is attached hereto as Exhibit 99.1. 1 EXHIBIT INDEX 99.1 Presentation by Prof. Wiesaw J. Cubaa with Title: Long-Term Data for GH001 in Patients with Treatment-Resistant Depression 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GH Research PLC Date: October 14, 2025 By: /s/ Julie Ryan Name: Julie Ryan Title: Vice President, Finance 3